RUNX1T1 and acute myeloid leukemia: A previous study demonstrated that AML patients with RUNX1::RUNX1T1 and KIT mutation in relapse after allo-HSCT show a rapid response to avapritinib [14, 23], 80% of such patients achieved the decrease of RUNX1::RUNX1T1-positivity transcript levels after 1 month of avapritinib treatment for MRD [14].